5 c

a,
P a ,
P
A
~ n n i ~ ~ a n i u u a s u a n u i n i a ~ ~ a i ~ iiignssu
s ~ ~ r aaa. . a s u o n ~ n G a ~ i n n i % ~ G i < ~ u
u-
dua
3. & a d ~ ~ u u u a ~ d ~ u u i u n r r w ' u d ~ ~ ~ a m a ~
P,
aauasea"u!~uniwGi aaa:GiuinJ~sm~9i~w"uG
iau
d
l
2
~auasmierG!~nwsla:a~i~+u~n~ua~iu~?suaaosi"uu
%ajrn~riiuid~s~iluai~i~
auu u
5.vl~n~$udLLuadW'uaaunn%a
aw%i:Imu
ddd
u
.ss%u.aiBa~uas~u~auam%a~:!~wuinn<ibauasi
"bi+ M%3+6ii@il19
6.
&add~;~eivlis~li;naauasdriiuiuiInn
n'asGi%Ggnriau?uds:niuanua aisil:bnunis~a
wam i s eiis ~u aans ~m
wyads 5 % abuasuis
~
. r r ~ n a i g ~ i u i i i k i w 5wau%i%uaans~~a:via~un
n
ailu6u
7. ?Jn u~ u i M ~ ~ H M I ~ L L & Y ~ ~ L L ~ ~ ~
nasgtGn& riauGi"b?ud~:wiu
aw%i:aig~::
Gi%~s"~iimaini%aaw"~iadu6u!C
!a~uasesaiuaC?
AUI : n e s I n a w i n i ~n ~ ~ e w i G2u5, 2 I . m i ~ i ~ b l a m d ~ ~ ~ i i a i ~ i ~ ! w e ~ % u ~ a u 6 ~ w100
! ~ eni iau~ i ~ p a " n
~ l i i l n u i l m a B . ds a i u h i u u iIn$~9katduumaum ~ U L Z ; A Y 1 ~ L w ~ l ~ ~ l m ~ ~ ~
P
din~~~aGn~ait;mds:nu~u~~u~iuuia~~iain
I6~ari6 a ~ z i u i r( 6 a ~ T a u~ 9 % 62~1d
d a i u u u~g?inwt a ~ a t a F i ~ l ! T n 1 ~ 6 i u i iaaua~lu
~
n$uf~ui~oiimiiuun&
!&bfi
aauaonlui a u a ~ b~uu$l,oil beetles, blister beetles,) a ' h u a ~ a ~ g n
iaanu
a i n a u ( L L ~ J ~ J ~ uaumtwiu
IU,
,uauw$~!i) u a u LLBJiiimaamiuiads:uim 3 - 5 a~~uGiaums
u
d
sa~9';osuugn 3 bbrn~lwimuai~iiiKaaauasniu8
a b u a ~ d o ~( vh u a ~ M r )
3. ntjuGn&
a , d o
ailuniuAuunainntjud 2
at~al%aanu'111?~u
(cantharidin)
A
~JL~~~I%%%I
~ ~ u a ~ u d w u l u u u a ~ T u(Lytta
n ~ d vesicatoria)
u
n~u~n$rrti7~~uBni~nwmt~~9GuuKumaum
~duKuBna:fiuailu~dps~~nin~uiiiKa
din~ilu
a i s < ~ i l u n i s n s t ~ u d s t n i n f i ~ 4 w ' uJ ~
s u~sBt ni
d a t l u r r i n i ~ m s u w n u "~ d s g n s u n ~ u n i ~ ~ i ~ u a t
aGmaaitgm~wiainiauriiuuu~~?w:~~a;~~iiuu
n i u i s n ~ u ~ ~ n u ~ i ? ~ u u u n u i !i6dw
u g" u
n i~? w u j
l ~ i ~ i n ~ i u u u ~ 1 I6aari
1 i $ ~Gniu,
Ji L ~ J
a r f i i h i l i l u d u w w 9.1 u s n a i n f u a ~ n w n i y G u ~ i l u
4. n ~ u u u ~ a a u a ~ ~ s d ~ au i~~~auhu. 2~ n~ ins u~ w ~ ~ w $ w " i a i ~ s t u u n i s w " i ~ i u " ~ u ~ ! m i ~ a t
wan
oTuarBuw'u$ ~ I ~ $ ~ ~ ~ ~ ~ ~ ~ ~ ~
4.1 b ~ t r k ~ a J ~ ~ ? ~ o l !&Lfi
~ l n 1U f3l ~ w9 ~~ ~~~ n l s < ~ t ~ s l n l s L $ udan<04auLLss
~$~
ddQ
ath.4 UflLLflJ
( ! i ~ b a ~ ~ ~ d u~f ul u)l J, ( u f l ~ g J ) ,
LLIJ~J~
(umiBn)
U
*
a,
B
a,
~
:
L
W
s a u n ~ n a i a u u aHJ~ i o aletbmu
fiaa12~a~ws';o~
$orlPsunws ranzwlu
damlud3zLnR!nuG 1 3 aQn dwuilnubnufiuuh
4.2 ~iluaua~ddfTolwinispa"aoi9n~9ia!~iaBu?I?ni 2 aGm iiu Egicauta hirticornis ( m w d 1 )
d n R K wann'iqn 2
Bnat~nduufh.i?.qdi19 us: Mylabris phalerata ( m w A 2) b o i s i o o i u
d
~
a,
d
d
asraGuBn ~ d o ~ n i r i ; ~ u ~ n u n s r ~ " u B n ~ ~iiu
~ l Bu swi u. !2~~5 2 8 a i a u i u nwuaJaJ a . K n y iiu
,a,
uu&~iun
k !&bri u u a ~ b r iw~adaamssm:dGBn
i
h J & i u a G m Epicauta hiificornk lflub$uiil.a"bilu
u
d
c
2. uqua 1~aonls:6u. ~mfls.iins:gniknasr~~du
ainia%uninm:a"eaaoni~usanCauasd~:iw~her
[Paw e r i ~ w u ~ d ? ~ ~ i P a w e r i ~ i a n ~ u ~ / 1 i G m ~ ~ i l ] .
nini~iQaiweri,~m~~iweri~u.nqs~wwxrniuns:
n i w d I 6as$iah : Epicauta hirticol
y n n s n a b a i i n u i b ; 2525.
nisnsu?wuiqiwn5nisiiwweJ" n%wd 3; 3 - 4
Fuaimu 2533;
a -
a
m ani17waseraweri~ian5
m w d 2 ~ a s z l :~Mylabris
u
phalerata
sinismgu. uuwyq: nruinuimsmimsuww6;
2533.
p 9 7 n z <i4plilliTd
/
/
6. q q ~ i n Gunhias,
s
8sn ~ u n ~ s w oy.+126i
d,
mas:,
t n l Cun5nilias, s i u r l u f i w 6 ~ rnsuylnn
~.
-
ilisGGsKm&aauasauraynrsr9siw
=,-
aniuw~~s5nuimaaa'aisism~a
Hepatitis C Virus Infection among Male Inmates at Klong Prem Central Prison: Study on Prevalence
Incidence and Risk Factors
qsu asGGY* u a u
uwnu"asiw6-J-rswsw'
s i a ' l u n i I s u u i k 6 - i I r u 6 was6uiiux a i n ~ $ u ailGysi%o
wsw'yiw6 ~ Y s i u *va: ?aGns l u s a -
* nmuua~oanui~ian~aisisruqu
n s u i w oi~ianimsuwnu"ww ns:wsaanisisruqu
a,
P a ,
P
u.nGmn:im?ds;aran'
siosiunnuds:~wnwuiin~u$&s54uwnu"~uadsmsln~$e!aia&uailuwnu"au$
.uinnirldui~awGm~muwnu"iriauiuwnu"~uniulu~isu~i uwnu"uwnu"duimu'syaludst~wfi!wo
tYnsinisG~~$'s
HCV aat~u$ouwnu"~ususs~6ssujaia!wu
(HCV)
i ~ m r d n wW
i n a i u a i a i a ~ n s $ 6 s s ~ s a i689
o
nu
?:Mils
W.R. 2 5 4 4 - 2 5 4 5 ImoRumw&iriaua~a~n~a
gi
aiusiu$!6:nwi
IuL?suiinaisnaosuwnu"dsu uwnu"iluuwnu"as1
5 lisu
l ~ ~ lL dL R~: .L ~P I : L ~ s ~ w ~ ~ ~ ~ ~HCV
I ~ ~ 6'2~
~ L ~ ~
a a h u i ~ ! a T i i iinn:piilu~uLiosd$uw"ub"n"unis~mb$s HCV h u Stata Intercooled version 6 n i s
~nwidt~u~unisuasbnssnis~n~i~u~u~mwusa~~saujdiiu~ub"~unis~m~C~sa!siua:!a~adu
A
.asciiunisGuismiuinnm~n~sunisGuisruinis~nwi~~oluuyw6
n s r w s a s a i s i s m y w.n. 2 5 4 4
s r n n i s i l n w w u n i s ~ m t $ o HCV +-~uau 3 0 9 q i n 6 8 7 s i o i%aLilunaiu;n
Confidence Interval, CI; 4 1 . 2 0 - 4 8 . 5 7 8 1 M & u i n ? n m u 1.740
lnri 1 0 6 n o 8 a L i l u q ~ i n i s & 73.08 s y n n s - 9 [ 9 5 %
44.85% [ 9 5 %
~nna- tau wu$inL<s
HCV s i u
CI; 59.88-88.44% PY] ~ l u g o ~ i u s d d
~ o h 6 ~ w i ~ a i i G r n s G mHCV
d s l u t j & s s Q a i u uinni;iinsi:MCnisnmnso
as4aGn!dufiij'ids:TGad
u i ~ a w l m i n ~ G i ~d ri ai us s u u s i n m s i m u i ~ G i ~ Bd ui a s s u u ~ n G u n i u u i i s n i u~ilu~?.a"uibaw?imimbiTi
b ~ u u i u n a 7i 9 d d ~ : ~ ~ b n u ~ u n i ~ ~ i ~ m n i s ? i m u i r i a u 6
(Adjusted
a s % w wodd ratio, pc 0.01 )
False Positive Anti-HIV Screening Test; A Retrospective Study of Anti-HIV Confirmation During 1 992-200 1
a-
Pa-
a
a m u u ~ s u ~ w u i n i a a ~ a i a i snsuf
m q ~n u i n i a n i n i s v w n u "
n i s m - l a s ~ ~ s ~ n i a ~ m ~ $ u b a s i !1amsiiaadlju2inis
?iiiil?uniams2sf~s<uynna{d
uwgi
i[s~u~$uslsi~Pms~sKmnaas
dsn'usms2siuuirwam ns:ws~saiaismqul6aun~~uanisdljuTw.n.
2 5 3 9 % ~ m s a s ~ u ~ u % m e ~ a s a s ~ i 6 a u ^ a " s a a a s2~- m
3 ni~Imulallsi~"bsasZufiu6au
aus
Western blot
~
I
~
~
I
~
~
~
~
~
~
&
~
~
~
&+A
8
~ 1 ~0 ~WWIUUI
~ ~ \ Wb dW~ ~R n ~~ ~~ m~s i( w ~~ u~
2 Un dS~ a~ ~I d Uw u~
B
y
91nizBna-1 ~iluniadnwiuuuCuunklnul.a"Gu awaas~siuGuniuiiowau-rnainfPns~a
B
~nnsus~~a:~sasasiu~uinsu~nuiniaminiswnef~~at~n~a"~iu
s:~-iis w.n. 2 5 3 5 - 2 5 4 4 ~smaas
Zufiuhufi5ui2lurl;uu~sauiun'un: Western blot 3 ~ n s i t ~ n i s ~ d ~ u u ~ ~ d a s u ~ siuGuwa
Kmsins~s
u2nmud2ab2aiu's~almul.a"
Chi-square for trend
prani3dn~i n a a ~ ~ w u i n i ~ m s " n ~ s a ~ w w u " ~ ~ a ~ ~ n ~ a " ~ i u l s s " u ~ n i s a s ~ a ~ u ~ u n i s ? i m ~ ~ a ~ a
baswuimsa2u 88.576 s i u aaiugar 8.858 s i u li'wau2nms~82.360 a i u (92.98%) n l d w a W l 6
1.357 (1.53%) vataa2siuuiil6waau 4.875 ( 5 4 9 % )
2
$sbiluwau2ndaau~uni~as~s~mn~us
< i u ~ u ~ s a s a a ~ u ~ u a : aw.n.
i l a 2 5 3 5 - 2 5 3 9 i k u u u (r.0.972)
3
~ ~ h a m a s s : ~ iw.n.
i s 2539-2544
(r=O.770) ~ u u i ~ : d ~ ~ u ~ ~ r i u u a s ~ m s i m s a s b u e ~ " u(w
( 2a u
fora n
tend
~ ~ u= ~38.03,
u
p<0.001)
nr ~ ~ W P S R L U W
CIw w
I
~ T ~ R D O I L I T L ~ ~ UU ~ L V I T ~ ~ J ~ ~ : ~ U ~ T :2~ J.I ~6
w $ninlnu~~i~&ni~
w a w P
~~wwnkinmiuu?~~mui~i~~~~imrnrp~~ifa~~d~~~~~~a~~~iu~
V
Pa.
P
~n~uu~ouanai~ir~fmm~nr~~~~u~~~u2ts'dii0n~~~aann"iw'aniu~~ni~
UW-d
JuneynriJ~ivi~ ~ ~ ~ ~ X ~ ~ W I ~ ~ G ~ ~ I W L L ~~0u&~i~~aiults'ninl~u%
~ L ~ T J ~ . J ~ I U M I ~ ~ Q
- .*+: .
, j -
'
. -
g y
'.::
,k\.,,
:I
.:.I
U
.
&.,'f-
.
-
_
HIV-1 Transmission Rate among infants born to ARV treated mother during 1 9 9 7 - 2 0 0 4 : A retrospective
study from Lab Network of DMSC.
2
A4
u m ~ wi i ~ n w " n a a n ~ i n u i ~ n i ~ n n ~ " l ~ a<luau
~ a l i ! a1 5~,-0~0 0 - 2 0 , 0 0 0 nuiag duseiani3
1n~~uainui~ni~in~~j~n"b~eri6m
i u~~n~~?asa~n:ius tM~'uu s d ~ G I n i ~ ~ & u ? n n i u ~ m ~ ~ n i ~ ? n
~$aainuilni@-~-m
~ i n l a ~ i m s ~ a m s ~ l s l a d 6 o s 1~8o uileu$sssdwa!i'
iu
9
~n~asjiuhsd~%
nl3n3uinuialnnim~bbwwd i ' w " w u 1 ~ n ~ i uIn-house
i
HIV-PCR u l n j a i w.a 2 5 3 7 - & 9 h ?"a
< ~ 6 i i u n i ~ d ~ : ~ Z u d ~ : % ~ ? % n i w 1 u n ~ u ~ I n u i i a w ? n s ~ n 3~8n2~ u
n jiai er i ius i i u
i <~l vuh a
d 4 &'
sann$asnuas ELISA LLR: GPA ?auac 1 0 0 u a n ~ i n < e ~ ~ s ~ i u i m ~ a a % u ~ G n ~ n a u n a i n u i ~ n i ' ~ ~ n n ~ a a
iluKul~sw
uiuia t~us3iud~:aiybn3izps"w u i i i i m i u b n a m a i u ~ i ~ w i z ~ p i ~1 oo
K u La: 9 5 d a
b8nijuiq 6 iffuu 3qaljuLliuni3n32q~ui~nbdo?nniu~n34n~3anniabbw<b$aainbbi~tln
Prevention
mother to child transmission (PMTCT) L&a%$ui~im~lba:?nniu~m3ini3~nb$a~6n3aun~u~n~u~
~~3:~ds:h%wauusni3%$u16quI~ia~amAi'
P,
OI
4d
2 5 4 7 - 3 ~ ? Gd~? u d T ~ ~ n ~ i u i % M ' ~ d 3 t ? n %
3lnl?nRJ
n l ~ i ~ u~ ~
Uu
~ R S J T I PMTCT
I~
fu
di~ns:uin~nud~n~dr:ssdlvi~lfm~naaun~u~n&t(%ud~:~w~~"bwu
l n u a r n h r 1,8uGsriuayu~n
h u i & T w u i$nni=iIInauru Tmn7uun7niu6~aatnauquamniwnian3aa
lnun3aab8nbi;;aiquinn<i
1 tau an:v+is~in$uin 2 Lieu ~daIi'wamsa~d~n~~as
warnsdnai i . ~ u w.a
d ~ 2537-2547 I6sCuayw~nwnaaulss"n"u~niaiier?d~~$a
20.000 amnmaau
d
iliiu2uyn a i n s n ~ s i a u n i ~ ~ n e u s u ~ ~ ~ w u a : d i s d ~ t ~ n ~ i200
u i n nu
n i i~ n i a i i u s s " a ~ d ~ G i n 7 3 ? 6 ~ a ~ ? u
* O I
d
V
d
: ~ ~ ~ i ~ ~ a . ~ n r ~ n ~ ~ ~ a i a i r r n P~MuT Cl Tw l 6n 2s a~ ~n ii~r w ~ n i 2 ~ n ~ i 1 1 a 1 n i a i i e r u m ~ ~
k
a
:
>
d
~;-.g~i-c~.:;1:-~:1~.~1~ji~~~~~i~~~~gi]~~1~n~~~~a~i.j~u~~-~
.
4'
d
~~~$~-i:.~~--~~:~.:i.:---~-~;~~~~~
3 ,i :- :~~~ .~; :-v~a -~~~ r3r17n :i ;~. W
; -~~~~
g ;a ~
l p~d-n ~ ~ b $ p , ~
i
n
n
P
2'
.
uq3fli~~:$~~l;a~.:-.::i~~:23.8 i
adnnda~i"b?ueriGT
2
~ ~ n i ~h 29u n " E
=
.-h-:;F:-P-cr-t. . - ,.
1~952~".7?=
j
.
C
f
L
wuklII
<
I-ii$i.~a: 5.5 ~ia: 2 I.15 ~ i u i i i 7 1uanain
?Kc--,<,
-CF
;
- ~ ~ T 5 ~%:er:ib~dn%sni%
l ~ ~ i ~ ~ ~ i % i ~ i i 5 iZldovudine
~ ~ ~ ' 5 i ~ ~ PMTCT
~ ~ ~ ' wurdi~w31
i i ;
.. .
nisiionan~Ba~inui~~naw9~Lw~jii;iujiau9z
2,9 . j m r ~ n ~ u i ~ i ~ ~ ~ u e r i ~ ~ m ~ i n i14.3
~~nb~aiauaz
a 2 d a a t i e i s d inissiiu$sddfju~msnsaB HIV-PCR vadnsuf nuiflianfmsiiwn~muiinio~?lr
u l u u i u u ~ ~ n s m a a ~ m a ~ s m ~ u l u TPMTCT
n 3 ~ n ~aiw:ldiilu~n~s~iislun~sGn~~uds:2p?^bt-lauo.1
s
~ n w n i s ~ ~ R i i l i r r u i u w n ~ ~ ~ i n i s ~ n a ~ a ~ u m ~ n h i m ~3a i v i uu~i di1aduS~dts : ~ n t n i n
~ @ r ~ i u u ~ u ~ n ~ i u i ~ 1 i ~ u ~ d ~ d ~ ~ d ~ n i 5 i ~ ~ ~ & ~ i n ~ i~d idusi :d rwn 8n ~~ ~i ~
1 ~1 bf i~ au d~ ~w m ~ ~ i
s m ~ p n n i q dI ~o
ivi~h
i m : i i T e n ~ s ~ w u ~ ' i $ ~ n w ~ n < i b ~ u ~ ~ n ~ f ~ ~ ~i g~h~ ~
m nr -~is~~u~ ~ i u u ~ n $ u
~ i 3 ~ d ~ U ~ ~ ~ U ~ ~ ~ H ~ ~ ~ 2 i ~ ~ ~ n ~ ~ d ~ ~ l ~ ~ d d ~ ~ l ~ n 7 ~ 3 : ~ ~ % i ~ ~ R n i ~ 9 1 ~ H 9
l o o (u2n 1 9 nu 81 )
raa:Zdst2n~niw~unis~s~u~.ii,u~un~aGna$saaa!a4'i'1bnisn~Gna~ai~
6 r6vu
Staphylococcus aureus with resistance to vancomycin
u
C.e
P
n m u mu2w
~ u i ~ i i i n i ~ ~ ~ ~n s3u m
f n uy ~vm a n i m s i r w n f i
antiT~atiaqdsra~ffuTnnT3wui$a
MRSA wan21ubuiau1
vancomycin (VISA) ailun:jumdds:mpl
tjtuluq w.. 2539 ~ i I r i ~ ~ a n ~ u i i o n i ~ r r i ~ ~ ~ s ~ ~ u n i s ~ i w ~ an as::n ~i si~un"w~[ da~~uid$?sa &
VISA ~ u d s : a n ~ b u 0 n u n u w ~ ~VISA
a ~ sn k u s n I u 9 W.R. 2544 lnu p s - m ~ im~:t~naa~;3Nr LLR:RIU:
K s ~jn~n~~ai~lau1npJ"d!i!~d~1Qlan1sa~u5$naiia~ln~a~
d
VISA ri,lliquTnis&ut8aCsuuin
P W
~ui'diu
P
klidn; amuu2ilu2nu~~liania~~i3blb~"~nsu~nu1~1a~~nisaaw91eJ"b~dn~ibba:b~7s:a"9~$0~l~~insrildiabiia~
ad
- x n i s Z n w n a a r e u ~ Cs aureus 8 6 2 a q u ~ u f & ~ m ~unmnu
~ s u 2546
a ~ u 2547
~ ~ u
h B 1 5 6 l u j a ? h 10 %En
Amoxicilliniclavulanic acid (AMC), Clindamycin (CLI), Co-trimoxazole
era
(SXT), Erythromycin (ERY), Gentamycin (GEN), Oxacillin (OXA), PenicillinG (PEN), Vancomycin
(VAN), Fosfomycin (FOS) bba: Teicoplanin (TEI) 6'2ufZ disk diffusion (Kirby Bauer) ira:'Ml~l MlC
"~aderiVancomycin Gauaaduuiiia?~=jd E-Test
t r a n i z ~ n awln0ub$u
i
MRSAisua: 48.7 ( 4 2 0 m u k d ) aril: MSSA~CIUR:5 1.3 ( 4 4 2 BTU
~ u f MRSA
)
& i s AMC, CLI, SXT, ERY, FOS, GEN, -rEI u a t VAN faun: I 0 0 . 38.8, 95. 9 7 . 1 ,
1 1.9, 91.7, 0.2 raw: 0 aiudii'u MSSA ~ouii'dnii~niudii'ur~u?auw:1.6, 2.5, 2 , 4.5, 0, 1.4,
A'
0.5 var o wuri~MIC u m u Vancomycin
~
i s a a s S. aureus d n n s e u R r r u n a;a:~iv 0.5-3.0 p g i m l
% i s d ~ ~ a z a 2IL$B:U~!~WUL$~
d
VISA ~inni~aili~::jdiiuaJ~
L L ~ W U L & MRSA l$
MIC
ii u a ~ u i
Z A
;~$ud~
3.0 p g / m l ~11%~ui~u21<un~sG%uiVancomycin u s ~ ~ $ s t i u uau~ a : ~ i l u g n y ~ l u
n i s i n w ~ d i h u ! d w a u i m i s ~ ~ ~ ~ ~ n i m m s ~ n n i u n i ~ r ~ i u u a i VISA
~ a ~deiuafinCis!d
aiu~"ufa~s
Vancomycin
m 3 p ~ ~ l M u ' a i l d ~ l u w " U ~ 3 t ~E" IlI Zl )~~ L~& W
I
Vibrio parahaemolflicus 0 3 : K 6
l~dsrandnu
Emergence of the pandemic potential of Vibrio parahaemolyticus 0 3 : K 6 in 'Thailand
unhuatinqds:aan'
I J A S I R T S ~ S U G ~ U T ~ ~ ~ T $ T Z U L ~ B ~ ~ Gvibrio
U~~EITLM~~T~L~
parahaemolyticus W.R. 2539 a f i n n l s % r u l n J 1 %(pandemic)%u~aler
~~
~)E)~:~wR~I~~o~~~L~~:BP~<s~~~~
2 2 2
ain~Qnbbauaawi:wiuw"paf 03:K6 ~ i ~ i u d s r b n ~ ~ ~ u ~ n i s ~ ~ i n v a ~ s i ~ i s i i l ~ b ~ u a i n a ~ o z a a w
?d
PI
'
'
P
S
a
JZ
C
=
0
2
;'
.-
E
8
f
Q
EW c
c
. c
. b5
. a
.
-8%
:
p
. -vs
(a
@
a"
0
r. g .-y=
( a m
'
.
,
. $
a
'Z
%
5
-c 2
5
*
a
@
a
o
o
0
.s
.y
r
G
0
.o
0
ti
<
.y
ti
0
-.-.. -.-..
"e
: "
"
.
.
.
.
.
.
.
.o
E
C
X
o
x
2
E
W
Q
2
CI
E
W
Q
CI
o
CI
.-4
C
. G G
.
'
.
'
'
.
2
C
'J
E
G
'0
C
F
EJ
1
0
3
0
C
3
$
(C'
r
P
G
G
'0
9
5
c
K-J
3
1
0
G
'i
nl%m%asvlifiuimalkaline phosphatase
l$wniiauem:rniaq~6uvassiaCi~ 6'1
3.
(AP)
~~haa$abmuk3!d~~ww66s:~%us7nn7a.a"nda:a"G
4 . n i a a a a s w i d 5 u i m gamma-glutamyl
a 7 n x n ~ ~ u ~ i l u u ~ r i a u t k m ada:%rnal6?u
inia
transferase (GGT) ~gu~aul?iljndwuu?nd~~aBGu
T R ~ Us~6sda:TGnialC?ua"am~~az~r:~~a:nau
~ ~ c i i a 7 s w u 1 ~ d a ~ a $ ~ ~ ;ms I$~ui ~i naaui u i 7 ~ w i c
vasa:am niamraa! a i n i a n i u u a n + i ~ n i un i a ~a7:wuinGn
5. nlamaaew7d?ulm albumin L f k 9 ~ 7 n
A' dor
~~ubda~uWda5is"uuwmu
$lei&uinaiut%
dnG d 5 u l m albumin %u~:oms:amas&n47dnG
albumin
adaso7n
nismsaqwi9amiimGGm
prothrombin
~3ubdsftuWdiaeih
n l s ~ s ~ s M l m ~ t n l s ~ n L ~ u "mLa I~ a~ 9i sbngi vRa ~s ~~ ~~a m $ s n i i s s i n n t ~ ~ a u A i n a ~ u
bmermsaoM7d?u7mbaulg~
2 "oGn lbaLialanine ihdnmwmu s:Yii%~vlm prothrombin s:u:aaaind
2
aminotransferase (ALT) w?a serum glutamic pyruvic ~:amLb'&62 prothrombin time (PT) % U I ~ U I P ~ ~ U
transferase (SGPT) b~a: aspartate aminotransferase niidn;
(AST) w%~serum glutamic oxaloacetic transaminase
A
(SGOT) 1 ~ ~ % u n u d n ~ s : i d 1 a ~ a : w i3i 0s - 4 0 n i s n a a o w i s r ? i i < a 5 ~ i n u i
1.
n c i o r
~~uniamsaswiaia~~~uas6da:nauvasGa
L & ~ I ~(antigen)
? K wiaw7bdsduWd+~srnuahs
A ' d
vuLwamaunuasian7s~mb~a1a~R
(antibody)
2. niamaaevlid5u7m bilirubin bhniamaas
jf
ndtuulufisilui;$w~nnis Enzyme immunoassay
(EIA) $sin~iulaua:miu6i~w7:~sd a n d i ~ u ?
A
%:'MT679 antigen LLa: antibody "asvm:~!6l~sPdler
P,
nina?uaiu7anvasKulun7an"7~ma7aWdIi luld~mhuimaasfin3i:di7~is2ddaiuian~i
i'asniapsKsj,,7n~Gm~$am~~msaamn
%unudnGid7
b n u y n a i n s l u 6 s d i G m s ~ a s~ i a l $ ~ n ' : a s i a
iTmbuGi
gadw~nlud=xLnnbu i~s:Gi~hsin Laardek
ailaasintJd~nuint$a~a?a~uiYnLau.ii
24'
i a u I w ~ s : n a i u ~ i l u $ ~ n ~ a a ~n'9tuns8d
sa~a
Fiiad~:LWFI
I. %a?aKuiYn~wu~aaiuiaomjlaawi
~ii<uniruaaiianiudmauauaaiani-rin~$e2
m179WU Anti HCV 1 ~ b ~ a n ~ u ~ ~ l n ~ : L i ; l ~ ~ 9 n l a :
A d 4'
i~a:muimnwi~~nnalum'
nu~saIun~:~~a~fian
Ad
-
aQn IAa~riAnti HAV I ~ M
~iiuniifur~ud=iianiu 1un~unuamnnis~n~8aii
ueni~m-ras
Anti HCV
a
ibania~?lwwauandaau%G
8ana%iini%m%as
a5imuU%u~:u:aa~nuaania?n~aa
Eiauannia:
nis?na$ab5uuw$u sl"?maaswus:~~ana-dium: BuGuy n n u TnuIa'bnnQn R e c o m b i n a n t
>
~ u ~ i a m u f i i ~ a ~ i m s ? n b $ a ~ a ? ~ & u ~ n b a u immunoblot
b a a ~ ~ n t i assay (RIBA)
HAV total ab
=u
:ib
:b%n
biluwiinm%dla'HCV
~ i i u ~ i i ~ ~ u d i i a n i u a i i a 6encoded
u l u recombinant antigens aaa:
~~a:a:u:w$auaanis?nb$a
Ei~u
en31
synthetic peptides uuunu nitrocellulose nnswi antibody
d
iianiu%Ga~iani6urYuia~$ala?a6u~n~~u~a
<i~wi:ialaia&uiYn~auG~ ~ i l s ~ r i u i ~ n h u i
91
9
d~ais~d~iw5"ElmsasduGu
Anti HCV $iwdiu
6ua~awesia~nulGYuTn.iiu"b?a&uiYn~au~auiriau
4.la?aKugn~auGi%a7$msaswiqiifu;u
n~$niraQn~aiuisna~~Gmaan~d
! 2 ? a $ ~ k b%Gbbfi
~~~
2. %a?a&uEn~auiaiui%nm.jap~idau
2 ' "
Anti HDV IgM Eiauannia:m%inb$ab~uuw~u
dsmauuaab$eua:~iifun"uiabaaw"aw~~~
6 %En
Anti HDV total ab ~iauonnia:ni%inb$a
l6'bbfi H B S A ~~ilubd~ludauds:nauiiauaab$a
%a?a&uiYn~aud
Liauanniacnis?na$a~5uuw$u
LGU~W
Kubba:Sa?a
sl"?m~a~wus:~~ana~ium:~uiianiun"i$aini~5.!aia&uiYn~aut Iaifmsaswi~iqunir
?nL$ala?a6uiYnauda pi"sa~iluwiw:uaa~$a
Anti la?a&uiYn~aut
!Guri
v
~ B s ~ i l u ~ i { u h i a d a u ~ a v a s i < a ' b a ? a ~ u g n ~ a u hAnti HEV IgM Eisuonnia:ni%inb~ab~uuw$u
a
d<isniua<iavu%u%:er:~a%nvasn7cj~n~$a Ei~uan
Anti HEV IgG ~ ~ u ~ n ~ i i i ~ n - ~ n ~ n u ~ ~ i u
~ i i i a m u l ~ ~ 5 i a ~ i i ~ ~ n i l a ? a & u i Y n ~ a uh?aKugn~au8
d~uuh
uatiiiisqi7$'ur7&'ubbi'a
w~abnu~&?u~n~u%a?a&uiYnbau!uiriau
Anti HBc
6. !a?a&u
iYnaau8 %uusla:~~~~s'b~aiui%n
bilu?iifuniaisdauununaia (core) uaab& ~ ~ u l i ~ m s n s ~ s n l a er~l l u 2 ~ ~ ~ ~ u ~
'4
a
~a<ianiua<iauu%u%:u:~~%n"~aani%in~$aEia
msmsaswiai~viuqnssuu
aa ~$alaiaKu
uan-dibia%&?uni%?na<a!a?a6uiYnbaud
Anti HBc
gnaau aaunis~ue~"unia:ni%~mb8a1~
biaasin
IgM
total ~b Eisuannia:ni%~nb$ab5uuw$uwTa&a7a
HBeAg ~ilubdsludauds:n auuas~$alaiaKu
d~uimua~ai~Gu~n~~uua~18addua~~u~~ani
~uuinnisncjai3~aaIa~~nis~Au~iuaumcj~"u~na~u
iYn"nud Liauannia:6~~an"iKaini%~~Eia6aiafiu
bnu%%wKnni%
Polymerase Chain Reaction &w?u
<luaua; ua:muisnuwif$um'nnti HBe Ei~~lan
A
~
A
dd
~
r
r
"
~
,, A ,a
b$a%a?a6uiYnbaubav m a 118;: bilula%avuai~j
n~a:nis?nna~cja~a
w'sauansZa~u~unun~nnuu
vju;nnubiluaCn RNA b.rhai7nis RT PCR (Reverse
niu~%%uaiiw$sni%?n~~a
Transcription Polymerase Chain Reaction) %uni%
3. la?aKujmauGaiui~nn~as~i~ii(un"u
biu<luaumlGuanslu
daub$alaFa;ug nLau;
-
ia~$ala?a6uik~auG
bnunsasm~ntiHCV a;
iau%wnjbiluaGnIgG thmsapwua:Eisuan$a
a,
bilula~aiislsGuqn33ub~uaGn
DNA s:G
l w;n
,,,
PCR (Polymerase Chain Reaction)
bdabiu
nia:ni%?nb$a~aaisb~u~~W"anis?n~$ab~uuw$u
<iuaums$u;n%%u dauuea RNA wesia DNA d?n
~ i n ~ Z a n ~ ~ s ~ ~ u d ~ u i m a : ~ ~ a i u ~ ~ a n d i sYba?ti6ugnbauc
n " p a % d %6abn HBsAg , Anti HBs
;Y
d
d
aiu.n~~yas~.na~a?H&l$nbR'Uba
u q-j
,
tiiuisa7uasbs;iu RNA
M%I
d
d
9
aia:$
,
Anti HBc IgM , Anti HBc total , HBeAg , Anti Hbe
8
DNA fibfiu<iua~dbb$a
Yb~?ti6~%nbti~l$
Yb6bbfi Anti HCV
% n ~ n u n 1 3 ~agarose
1
gel electrophoresis
~ r h 3 a i i ~ T n u l % t i ~ s P a s dultraviolet
~~tid
h % & ~ n ~ t i u G i( nsaalawi:iJdauaiu6wu
%a?ti6ui"nbtiuc ) %6bbn Anti HDV IgM baa: Anti
HDV total
nisam4uu~aoejidaAoddm~a~"a9~~uKa?a
4 '=4
~u~n~~uni~~add~p1an15
%a?ti6ugnbtiui %6bafiAnti HEV IgM bbat Anti
HEV IgG
i~w?uniaailaaawi~bninzGn
I$~ai:~Zan
d
~ a u ~ i u 5a ijaggns
u
Quuun~iiuiawi:.nau~wa
i d a a a a ALT, AST, bilirubin abat alkaline
PI-
~a~6iG~"9'btia7ui~nisasaa%~~ufitiiuian
a f i u h a i i i s I ~ ~ a 5 u4 ~asmaratQua
~m~~~
d
phosphatase 6 i ~ d % ~ t i i ~ i ~ ~ ~ 3 ~ 9 ~ ~ ~ ~ ~ t i l ~ l 3 ~
n i s d ~ m s a s ~ i a i s ~ u ~ nb<alaia61~15nbapJ
ss~~aa~
~fiulu{abu qmm~ij4 a ~ n i ~ . n a ~ Q u a
di~?uniskaaaawi~~ijfun"u?w
ui
aai:a$encjihu<iuau
d~
5 ija88na Qinaun
A
a6uaawiz.rrauawo6daaaa HAV RNA , HBV D N A ,
1Qei:a8sn$diuSiraa11 5 ija88ma draa~un~nu
HCV RNA . HDV RNA . HEV RNA abac HGV RNA
d
b a w i : . n a u b w ~ i ~ n a a s ~ a ; j i ~ 6 ~ l ~I nb ~ w
a nuAnti
~ 0 L L s ~ l ~ , ~ u a 7 u l s n ~ d n a a ~ ~ ~ w ~ b6u1u
Mn~l~lan
d
W V
HAV IgM bbat Anti HAV total ab
d C
< L L ~ ; L $ J ~ W V- 2@0 ?oriaaaa$uti ~ " s e i i n i l
a%u$nsu?wu i ~ i ~ m ~ n i s ~ ~ w w e J b
nwn6~Gjsu;si !on'
U
U
I
LLWW 6 3 i l 8 ~ ~
b b1i ~
T9?I9~~
ns. Luiani wsw'qasam
uiseian3asani
yfhra'
ns. 7erzn1 L93nJR5TWG
uisqsisd L*SIZ?LGW
ns. qos dinsiuuw'
ns. k u i (ailiiau'